---
title: Drug Interactions - Mechanisms and Clinical Significance
type: content
phase: 1
status: complete
priority: high
tags: [drug-interactions, pharmacokinetic, pharmacodynamic, CYP450, clinical-significance]
created: 2025-11-08
last_modified: 2025-11-08
---

# Drug Interactions - Mechanisms and Clinical Significance

## Introduction

Drug interactions occur when the effects of one drug are altered by the presence of another drug, food, beverage, or environmental chemical. These interactions can increase or decrease drug efficacy, cause toxicity, or result in treatment failure. Understanding drug interactions is essential for safe prescribing, especially in patients on multiple medications.

## Scope and Importance

### Epidemiology
- **Prevalence**: 20-40% of hospitalized patients experience drug interactions
- **Risk factors**: Polypharmacy (>5 drugs), elderly, renal/hepatic impairment
- **Adverse events**: 3-5% of hospital admissions related to drug interactions
- **Preventable**: Most clinically significant interactions are predictable

### Clinical Significance

**Major Interactions**: Life-threatening or permanent damage
- Examples: Warfarin + NSAIDs, MAOIs + SSRIs, statins + azoles

**Moderate Interactions**: May cause deterioration requiring medical intervention
- Examples: Digoxin + verapamil, ACE-I + K+ supplements

**Minor Interactions**: Limited clinical effects
- Examples: Most food-drug interactions

---

## Classification of Drug Interactions

### 1. Pharmacokinetic Interactions
Affect drug ADME (Absorption, Distribution, Metabolism, Excretion)

### 2. Pharmacodynamic Interactions
Affect drug action at receptor/site of action

### 3. Pharmaceutical Interactions
Physical/chemical incompatibility (IV admixtures)

---

## Pharmacokinetic Interactions

### Absorption Interactions

#### Mechanisms

**1. Altered Gastric pH**

**Mechanism**: pH changes affect ionization and dissolution

**Increasing pH (Antacids, PPIs, H2 blockers)**:
- **Decreased absorption**:
  - Ketoconazole, itraconazole (need acid for dissolution)
  - Atazanavir (protease inhibitor)
  - Iron salts
  - Calcium carbonate

- **Increased absorption**:
  - Weak bases (better absorbed at higher pH)

**Clinical Management**:
- Separate administration by 2-4 hours
- Use alternative antifungal (fluconazole less affected)
- Consider acidic beverage with azole antifungals

**2. Chelation/Complexation**

**Mechanism**: Formation of insoluble complexes

**Classic Interactions**:

**Tetracyclines/Fluoroquinolones + Divalent/Trivalent Cations**:
- Cations: Ca2+, Mg2+, Al3+, Fe2+, Zn2+
- Sources: Antacids, dairy, supplements, sucralfate
- Result: Marked decrease in absorption (up to 90%)
- Management: Separate by 2-4 hours; take antibiotic 2h before or 6h after

**Levothyroxine + Cations**:
- Iron, calcium, aluminum
- Coffee, soy products
- Separate by 4 hours

**Bisphosphonates + Anything**:
- Take on empty stomach
- Wait 30-60 minutes before food/other meds
- Only water allowed

**3. Altered GI Motility**

**Increased Motility** (metoclopramide, cisapride):
- Decreased absorption of slow-dissolving drugs
- Decreased absorption from sustained-release formulations

**Decreased Motility** (anticholinergics, opioids):
- Increased absorption (more contact time)
- Potential for increased toxicity

**4. P-glycoprotein (P-gp) Interactions**

**Function**: Efflux pump in intestinal wall → reduces absorption

**P-gp Substrates**:
- Digoxin
- Dabigatran
- Rivaroxaban
- Colchicine
- Many chemotherapy agents

**P-gp Inhibitors** (increase substrate absorption):
- Verapamil, diltiazem
- Amiodarone
- Cyclosporine
- Quinidine
- Macrolides (clarithromycin, erythromycin)
- Azole antifungals (ketoconazole, itraconazole)

**Clinical Examples**:
- Verapamil + digoxin → increased digoxin levels → toxicity
- Clarithromycin + colchicine → colchicine toxicity (fatal cases reported)

**P-gp Inducers** (decrease substrate absorption):
- Rifampin
- St. John's wort
- Carbamazepine

**5. First-Pass Metabolism**

**Grapefruit Juice**:
- Inhibits intestinal CYP3A4 (not hepatic)
- Increases bioavailability of CYP3A4 substrates
- Effect lasts 24+ hours (mechanism-based inhibition)
- Affected drugs: Simvastatin, amlodipine, buspirone, cyclosporine
- Management: Avoid grapefruit juice or use alternative drug

### Distribution Interactions

#### Protein Binding Displacement

**Mechanism**: Displacing drug increases free (active) fraction

**Clinically Significant When**:
1. Highly protein bound (>90%)
2. Narrow therapeutic index
3. Small volume of distribution
4. Rapid onset of action

**Classic Example: Warfarin Displacement**

**Warfarin** (99% protein bound):
- Displaced by: Sulfonamides, phenylbutazone, salicylates
- Result: Increased free warfarin → increased anticoagulation
- Effect often transient (increased clearance of free drug)
- Clinical significance debated (other mechanisms often more important)

**Other Important Examples**:
- Phenytoin (90% bound): Displaced by valproic acid, salicylates
- Methotrexate: Displaced by NSAIDs, sulfonamides → toxicity
- Bilirubin in neonates: Displaced by sulfonamides → kernicterus

**Modern Perspective**:
- Most displacement interactions clinically insignificant
- Transient effect (unless clearance also affected)
- Metabolic interactions usually more important

### Metabolism Interactions

**Most clinically significant pharmacokinetic interactions**

#### Cytochrome P450 System

**Overview**:
- Responsible for ~75% of drug metabolism
- Located in liver (primarily), intestine, other tissues
- Multiple isoforms with overlapping substrate specificities
- Genetic polymorphisms affect activity

#### Major CYP Isoforms

**CYP3A4/5** (30% of hepatic CYP, 70% of drugs):

**Substrates**:
- **Cardiovascular**: Statins (simvastatin, atorvastatin), CCBs (amlodipine, nifedipine), amiodarone
- **Immunosuppressants**: Cyclosporine, tacrolimus, sirolimus
- **Antiretrovirals**: Protease inhibitors, NNRTIs
- **Psychiatric**: Buspirone, quetiapine, lurasidone
- **Antibiotics**: Macrolides (clarithromycin, erythromycin)
- **Benzodiazepines**: Midazolam, triazolam, alprazolam
- **Opioids**: Fentanyl, methadone, oxycodone (partial)
- **Chemotherapy**: Imatinib, vincristine
- **Steroids**: Testosterone, progesterone, cortisol
- **Others**: Sildenafil, aprepitant, colchicine

**Strong Inhibitors**:
- **Azole antifungals**: Ketoconazole (strongest), itraconazole, posaconazole
- **Protease inhibitors**: Ritonavir (strongest), indinavir, nelfinavir
- **Macrolides**: Clarithromycin, telithromycin (NOT azithromycin)
- **Others**: Grapefruit juice, nefazodone

**Moderate Inhibitors**:
- Diltiazem, verapamil
- Erythromycin
- Fluconazole (high doses)
- Aprepitant
- Cimetidine

**Inducers**:
- **Rifampin** (most potent, prototype)
- **Anticonvulsants**: Phenytoin, carbamazepine, phenobarbital
- **St. John's wort** (Hypericum perforatum)
- **Others**: Efavirenz, nevirapine

**Clinical Examples**:
1. **Ketoconazole + simvastatin** → ↑simvastatin 10-20x → rhabdomyolysis
2. **Ritonavir + midazolam** → ↑midazolam → prolonged sedation
3. **Rifampin + oral contraceptives** → contraceptive failure
4. **Rifampin + warfarin** → ↓warfarin → loss of anticoagulation
5. **Diltiazem + tacrolimus** → ↑tacrolimus → nephrotoxicity

---

**CYP2D6** (2% of CYP, but metabolizes 25% of drugs):

**Characteristics**:
- **High genetic polymorphism**: 5-10% Caucasians are poor metabolizers (PM)
- **No significant inducers** (genetic variation more important)

**Substrates**:
- **Antidepressants**: TCAs (amitriptyline, nortriptyline), SSRIs (paroxetine, fluoxetine), venlafaxine
- **Antipsychotics**: Haloperidol, risperidone, aripiprazole, thioridazine
- **Beta-blockers**: Metoprolol, carvedilol, propranolol, timolol
- **Opioids**: Codeine (prodrug), tramadol (prodrug), hydrocodone, oxycodone (partial)
- **Antiemetics**: Ondansetron, tropisetron
- **Others**: Dextromethorphan, atomoxetine, tamoxifen (prodrug)

**Inhibitors**:
- **Strong**: Fluoxetine, paroxetine, bupropion, quinidine
- **Moderate**: Duloxetine, terbinafine, cimetidine
- **Weak**: Amiodarone, citalopram, sertraline

**Prodrug Activation Failures**:
1. **Codeine in PMs or with inhibitors**: No analgesia (can't convert to morphine)
2. **Tramadol in PMs**: Reduced analgesia
3. **Clopidogrel affected by CYP2C19** (not 2D6), but similar concept
4. **Tamoxifen + strong CYP2D6 inhibitors**: Reduced efficacy → worse breast cancer outcomes

**Substrate Toxicity**:
- **Fluoxetine + TCA**: ↑TCA levels → cardiotoxicity
- **Paroxetine + metoprolol**: ↑bradycardia, hypotension

---

**CYP2C9**:

**Substrates**:
- **Warfarin** (S-warfarin, more potent enantiomer)
- **Anticonvulsants**: Phenytoin
- **NSAIDs**: Ibuprofen, naproxen, celecoxib, diclofenac
- **Sulfonylureas**: Glipizide, glyburide
- **ARBs**: Losartan (prodrug), irbesartan
- **Others**: Fluvastatin, tamoxifen

**Inhibitors**:
- **Strong**: Fluconazole (dose-dependent)
- **Moderate**: Amiodarone, metronidazole, sulfamethoxazole
- **Weak**: Fluvastatin, zafirlukast

**Inducers**:
- Rifampin, carbamazepine, phenytoin, phenobarbital

**Clinical Examples**:
1. **Fluconazole + warfarin** → ↑INR → bleeding (very common)
2. **Trimethoprim-sulfamethoxazole + warfarin** → ↑INR
3. **Amiodarone + warfarin** → ↑INR (reduce warfarin dose 30-50%)
4. **Rifampin + warfarin** → ↓INR → thrombosis

**Genetic Polymorphisms**:
- CYP2C9*2 and *3 variants (reduced activity)
- Higher warfarin sensitivity → lower dose needed
- Pharmacogenomic testing available

---

**CYP2C19**:

**Substrates**:
- **PPIs**: Omeprazole, esomeprazole, lansoprazole (NOT pantoprazole - less dependent)
- **Clopidogrel** (prodrug - critical!)
- **Antidepressants**: Citalopram, escitalopram, sertraline
- **Benzodiazepines**: Diazepam
- **Anticonvulsants**: Phenytoin (minor pathway)
- **Others**: Propranolol, cyclophosphamide

**Inhibitors**:
- **Strong**: Fluvoxamine, fluconazole, ticlopidine
- **Moderate**: Omeprazole, esomeprazole, cimetidine, fluoxetine

**Inducers**:
- Rifampin, carbamazepine, phenytoin

**Clopidogrel Interaction (Most Important)**:
- **Clopidogrel is prodrug** requiring CYP2C19 activation
- **PPIs (especially omeprazole, esomeprazole)** inhibit CYP2C19
- Result: ↓active metabolite → ↓antiplatelet effect → ↑CV events
- **Management**:
  - Use pantoprazole (less CYP2C19 inhibition) if PPI needed
  - Separate dosing (clopidogrel at night, PPI in AM) - questionable benefit
  - Consider prasugrel/ticagrelor (not prodrugs)

**Genetic Polymorphisms**:
- 15-20% of Asians are poor metabolizers (PM)
- PMs on clopidogrel: Higher CV event rates
- Alternative: Prasugrel, ticagrelor (not prodrugs)

---

**CYP1A2**:

**Substrates**:
- **Methylxanthines**: Theophylline, caffeine
- **Antipsychotics**: Clozapine, olanzapine
- **Antidepressants**: Duloxetine, fluvoxamine
- **Others**: Tizanidine, ramelteon

**Inhibitors**:
- **Strong**: Fluvoxamine (increases theophylline 5x)
- **Moderate**: Ciprofloxacin, mexiletine
- **Weak**: Oral contraceptives, cimetidine

**Inducers**:
- **Smoking** (polycyclic aromatic hydrocarbons)
- Charcoal-broiled meat
- Cruciferous vegetables (broccoli, Brussels sprouts)
- Omeprazole (weak)

**Clinical Examples**:
1. **Ciprofloxacin + theophylline** → theophylline toxicity (seizures)
2. **Fluvoxamine + clozapine** → clozapine toxicity
3. **Smoking cessation + clozapine** → ↑clozapine (induction lost)

---

**CYP2E1**:

**Substrates**:
- Ethanol
- Acetaminophen
- Isoniazid
- Halothane (anesthetic)

**Inducers**:
- Chronic alcohol consumption
- Isoniazid

**Clinical Example**:
- **Chronic alcohol + acetaminophen** → ↑NAPQI production → hepatotoxicity (even at therapeutic doses)

#### Time Course of Metabolic Interactions

**Enzyme Inhibition**:
- **Onset**: Immediate to hours (competitive inhibition)
- **Maximum effect**: 1-2 days (depends on inhibitor reaching steady state)
- **Offset**: Depends on inhibitor half-life
  - Short t½ (fluconazole 30h): 5-7 days
  - Long t½ (amiodarone 58d): Months

**Enzyme Induction**:
- **Onset**: Days to weeks (requires new protein synthesis)
  - Rifampin: 5-7 days
  - Carbamazepine: 2-3 weeks
- **Maximum effect**: 2-4 weeks
- **Offset**: Days to weeks after discontinuation
  - Return to baseline: 2-4 weeks

#### Phase II Interactions

**Less common, but important**

**Glucuronidation (UGT)**:
- **Substrates**: Morphine, acetaminophen, lamotrigine, irinotecan, raloxifene
- **Inhibitors**: Valproic acid (inhibits UGT)
  - Valproic acid + lamotrigine → ↑lamotrigine → rash, toxicity
  - Reduce lamotrigine dose by 50%

**Sulfation**: Generally less prone to interactions

**Acetylation**:
- Genetic polymorphisms (fast vs slow acetylators)
- Isoniazid, hydralazine, procainamide

### Excretion Interactions

#### Renal Excretion Interactions

**1. Tubular Secretion Competition**

**Organic Anion Transporters (OAT)**:

**Probenecid** (classic inhibitor):
- Blocks secretion of β-lactams → ↑levels (used therapeutically)
- Blocks methotrexate secretion → toxicity
- Mechanism: Competitive inhibition of OAT

**NSAIDs + Methotrexate**:
- NSAIDs inhibit tubular secretion
- ↑Methotrexate levels → myelosuppression, nephrotoxicity
- High-dose MTX especially risky

**Trimethoprim**:
- Blocks creatinine secretion → ↑SCr (without affecting GFR)
- Mimics renal dysfunction
- Also increases K+ (blocks ENaC)

**Cimetidine**:
- Inhibits secretion of cationic drugs
- Affects: Procainamide, metformin, dofetilide

**2. pH-Dependent Reabsorption**

**Urinary Alkalinization**:
- Traps weak acids (ionized, can't reabsorb)
- **Used for**: Aspirin overdose, methotrexate toxicity, uric acid stones
- **Agents**: Sodium bicarbonate, acetazolamide

**Urinary Acidification**:
- Traps weak bases
- **Used for**: Amphetamine overdose
- **Agents**: Ammonium chloride (rarely used)

**3. Alterations in Renal Function**

**NSAIDs**:
- Inhibit prostaglandin-dependent renal blood flow
- Decrease GFR → ↓clearance of renally eliminated drugs
- Especially important with:
  - Lithium (narrow TI)
  - Methotrexate
  - Digoxin
  - Aminoglycosides

**ACE-I/ARBs + K+-sparing diuretics**:
- Additive hyperkalemia risk
- Include: Spironolactone, amiloride, triamterene
- Also: TMP-SMX (trimethoprim blocks ENaC)

**Additive Nephrotoxins**:
- Aminoglycosides + vancomycin
- Aminoglycosides + loop diuretics
- NSAIDs + ACE-I + diuretics ("triple whammy")
- Amphotericin + cyclosporine

#### Biliary Excretion

**Enterohepatic Recirculation Disruption**:
- Antibiotics kill gut bacteria → ↓β-glucuronidase
- Affects drugs with enterohepatic cycling
- **Example**: Antibiotics + oral contraceptives
  - Reduced OCP efficacy (controversial, but possible)
  - Safer to use backup contraception

---

## Pharmacodynamic Interactions

**Mechanism**: Drugs interact at receptor/site of action or through physiological effects

### Additive/Synergistic Effects

**Definition**:
- **Additive**: 1 + 1 = 2 (combined effect equals sum)
- **Synergistic**: 1 + 1 = 3 (combined effect greater than sum)

#### CNS Depression

**Agents**:
- Benzodiazepines
- Opioids
- Alcohol
- Barbiturates
- First-generation antihistamines
- Z-drugs (zolpidem, eszopiclone)
- Muscle relaxants
- Antipsychotics (sedating)

**Effects**:
- Excessive sedation
- Respiratory depression
- Falls (especially elderly)
- Motor vehicle accidents

**Clinical Management**:
- Avoid combinations when possible
- Reduce doses if combination necessary
- Patient education about risks
- Avoid alcohol

#### QT Prolongation

**Mechanism**: Block cardiac K+ channels (IKr, hERG) → ↑QT interval → torsades de pointes

**High-Risk Drugs**:
- **Antiarrhythmics**: Sotalol, dofetilide, amiodarone, quinidine
- **Antipsychotics**: Haloperidol, ziprasidone, thioridazine
- **Antibiotics**: Macrolides, fluoroquinolones (moxifloxacin > levofloxacin)
- **Antifungals**: Fluconazole (high dose), pentamidine
- **Antiemetics**: Ondansetron, droperidol
- **Others**: Methadone, arsenic trioxide

**Risk Factors**:
- Female sex
- Hypokalemia, hypomagnesemia
- Bradycardia
- Baseline prolonged QT
- Genetic (congenital long QT syndrome)
- Multiple QT-prolonging drugs

**Management**:
- Check baseline ECG
- Monitor electrolytes (K+, Mg2+)
- Avoid combinations when possible
- Check QTc periodically

#### Bleeding Risk

**Additive Anticoagulation/Antiplatelet**:

**Combinations**:
- Warfarin + aspirin
- DOAC + aspirin
- Clopidogrel + aspirin (often intentional - dual antiplatelet)
- Triple therapy: Anticoagulant + dual antiplatelet (high bleeding risk)

**NSAIDs + Anticoagulants**:
- Additive bleeding risk
- NSAIDs: ↓platelet function + GI mucosal damage
- Increased GI bleeding especially

**SSRIs/SNRIs + Anticoagulants**:
- SSRIs/SNRIs impair platelet serotonin uptake
- Increased bleeding risk
- Especially with warfarin, NSAIDs

**Management**:
- Use combinations only when indicated
- PPI for GI protection
- Monitor for bleeding
- Consider lower doses

#### Serotonin Syndrome

**Mechanism**: Excess serotonergic activity

**Agents**:
- **MAOIs**: Phenelzine, tranylcypromine, selegiline, linezolid
- **SSRIs/SNRIs**: All
- **TCAs**: Especially imipramine, clomipramine
- **Opioids**: Tramadol, meperidine, methadone, fentanyl
- **Triptans**: Sumatriptan, rizatriptan
- **Others**: St. John's wort, MDMA (ecstasy), methylene blue, linezolid

**High-Risk Combinations**:
- MAOI + SSRI (most dangerous)
- MAOI + meperidine
- MAOI + dextromethorphan
- MAOI + tramadol

**Clinical Features** (triad):
1. **Mental status changes**: Agitation, confusion
2. **Autonomic hyperactivity**: Tachycardia, hypertension, hyperthermia, diaphoresis
3. **Neuromuscular abnormalities**: Clonus, hyperreflexia, rigidity

**Management**:
- Discontinue serotonergic agents
- Supportive care
- Cyproheptadine (serotonin antagonist)
- Benzodiazepines for agitation
- **AVOID MAOIs + SSRIs** (2-week washout minimum, 5 weeks for fluoxetine)

#### Hypertensive Crisis (Tyramine Reaction)

**Mechanism**: MAOIs prevent tyramine metabolism → NE release → hypertension

**MAO-A Inhibitors**:
- Traditional: Phenelzine, tranylcypromine
- Reversible (less risk): Moclobemide
- Linezolid (antibiotic with MAOI activity)

**Tyramine-Rich Foods**:
- Aged cheeses
- Cured meats (salami, pepperoni)
- Fermented foods (sauerkraut, soy sauce)
- Draft beer, red wine
- Fava beans

**Contraindicated Drugs with MAOIs**:
- Sympathomimetics (pseudoephedrine, phenylephrine)
- Dextromethorphan
- Meperidine, tramadol
- SSRIs, TCAs

**Management**:
- Dietary restrictions
- Medication avoidance
- Phentolamine for hypertensive emergency

#### Hyperkalemia

**Additive Mechanisms**:

**Combinations**:
- **ACE-I or ARB + K+-sparing diuretic**: Very common
- **ACE-I or ARB + NSAIDs**: Reduces renal K+ excretion
- **ACE-I + ARB**: Dual RAAS blockade (not recommended)
- **Trimethoprim + ACE-I/ARB**: TMP blocks ENaC
- **Heparin + ACE-I**: Heparin ↓aldosterone

**Risk Factors**:
- Renal impairment
- Diabetes
- Elderly
- High dietary K+

**Management**:
- Monitor K+ regularly
- Avoid high-risk combinations
- Dietary K+ restriction

#### Hypotension

**Additive Vasodilation**:
- Multiple antihypertensives
- Sildenafil + nitrates (contraindicated!)
  - Both ↑cGMP → severe hypotension
  - Can be fatal
  - 24-48 hour separation needed
- α-blockers + antihypertensives
- Antipsychotics (α-blockade) + antihypertensives

#### Nephrotoxicity

**"Triple Whammy"**:
- **ACE-I/ARB + NSAID + Diuretic**
- Mechanisms:
  - ACE-I/ARB: Dilates efferent arteriole
  - NSAID: Constricts afferent arteriole
  - Diuretic: Volume depletion
- Result: Acute kidney injury

**Other Combinations**:
- Aminoglycosides + vancomycin
- Aminoglycosides + loop diuretics
- Amphotericin + cyclosporine
- Contrast + metformin (lactic acidosis risk)

### Antagonistic Interactions

**Definition**: Drugs oppose each other's effects

#### Examples

**β-blockers + β-agonists**:
- β-blocker blocks bronchodilation
- Can precipitate asthma exacerbation
- Avoid non-selective β-blockers in asthma

**NSAIDs + Antihypertensives**:
- NSAIDs antagonize many antihypertensives
- Mechanisms: Na+ retention, vasoconstriction
- Blood pressure increase: 3-5 mmHg average

**Levodopa + Antipsychotics**:
- Antipsychotics block dopamine receptors
- Reduce levodopa efficacy
- Worsen Parkinson's disease

**Cholestyramine + Many Drugs**:
- Bile acid sequestrant binds drugs in gut
- Reduces absorption of:
  - Warfarin, digoxin, levothyroxine
  - Fat-soluble vitamins
- Separate by 4-6 hours

---

## Food-Drug Interactions

### High-Yield Interactions

**Grapefruit Juice**:
- Inhibits intestinal CYP3A4, P-gp
- Affected drugs: Statins (simvastatin, atorvastatin), CCBs, cyclosporine, buspirone
- Effect lasts 24+ hours
- Management: Avoid grapefruit or switch drugs

**High-Fat Meals**:
- Increase absorption of lipophilic drugs
- Examples: Itraconazole, griseofulvin, ritonavir
- Can be therapeutic (give with food)

**Vitamin K-Rich Foods + Warfarin**:
- Green leafy vegetables (kale, spinach, broccoli)
- Antagonize warfarin effect
- Management: Consistent intake (not avoidance)

**Tyramine + MAOIs**:
- See hypertensive crisis above

**Calcium + Antibiotics**:
- Dairy products chelate fluoroquinolones, tetracyclines
- Reduce absorption significantly
- Separate by 2-4 hours

---

## Herb-Drug Interactions

**St. John's Wort** (Hypericum perforatum):
- **Potent CYP3A4 and P-gp inducer**
- Reduces levels of many drugs:
  - Oral contraceptives (pregnancy risk)
  - Cyclosporine (transplant rejection)
  - Warfarin (↓INR)
  - Antiretrovirals (treatment failure)
  - Digoxin
- Also serotonergic (serotonin syndrome risk)
- Management: Avoid; discourage use

**Ginkgo Biloba**:
- Antiplatelet effects
- Increased bleeding risk with anticoagulants
- Case reports of intracerebral hemorrhage

**Garlic, Ginger**:
- Antiplatelet effects (mild)
- Theoretical bleeding risk

**Echinacea**:
- May induce or inhibit CYP450 (conflicting data)
- Theoretical interaction risk

---

## High-Risk Patient Populations

### Elderly

**Risk Factors**:
- Polypharmacy (average >5 drugs)
- Altered pharmacokinetics (↓renal/hepatic function)
- Altered pharmacodynamics (↑sensitivity)
- Multiple comorbidities
- Multiple prescribers

**High-Risk Interactions**:
- CNS depressants (falls)
- Anticholinergics (delirium, confusion)
- Anticoagulants (bleeding)
- QT-prolonging drugs

**Prevention**:
- Medication reconciliation
- Beers Criteria (avoid high-risk drugs)
- Deprescribing when appropriate

### Renal Impairment

**Mechanisms**:
- Decreased drug clearance
- Active metabolite accumulation
- Altered protein binding (uremia)

**High-Risk**:
- Renally eliminated drugs (digoxin, aminoglycosides)
- Nephrotoxic combinations (triple whammy)

### Hepatic Impairment

**Mechanisms**:
- Decreased metabolism
- Decreased first-pass effect
- Decreased protein synthesis (↓albumin)

**High-Risk**:
- Hepatically metabolized drugs
- Drugs with high extraction ratio
- Sedatives (hepatic encephalopathy risk)

### Pregnancy

**Considerations**:
- Teratogenicity
- Pharmacokinetic changes (↑Vd, ↑renal clearance)
- Effects on labor/delivery

**High-Risk Interactions**:
- Warfarin + any other anticoagulant (bleeding at delivery)
- Multiple anticonvulsants (teratogenicity)

---

## Identifying and Managing Interactions

### Assessment Tools

**Drug Interaction Databases**:
- Lexicomp
- Micromedex
- Epocrates
- Clinical Pharmacology

**Electronic Health Records**:
- Alert systems (often too sensitive)
- Override requires clinical judgment

### Clinical Approach

**1. Recognize High-Risk Situations**:
- Narrow therapeutic index drugs
- Polypharmacy (>5 drugs)
- High-risk drug classes
- Vulnerable populations

**2. Predict Interactions**:
- Know CYP450 substrates, inhibitors, inducers
- Understand pharmacodynamic mechanisms
- Review with each new prescription

**3. Monitor for Interactions**:
- Baseline and follow-up labs
- Therapeutic drug monitoring
- Clinical assessment
- Patient education

**4. Manage Interactions**:

**Avoidance**:
- Choose alternative drug
- Best strategy for serious interactions

**Separation**:
- Temporal separation (chelation, absorption)
- Typically 2-4 hours apart

**Dose Adjustment**:
- Anticipate and adjust dose
- Example: Reduce warfarin when starting amiodarone

**Enhanced Monitoring**:
- More frequent labs
- Closer clinical follow-up
- TDM if available

**Patient Education**:
- Inform about interaction
- Signs/symptoms to report
- Adherence to recommendations

### Documentation

- Document interaction identified
- Document management plan
- Document patient counseling
- Medicolegal protection

---

## High-Yield Interactions for Exams

### Top 20 Interactions to Know

1. **Warfarin + Fluconazole** → ↑INR (CYP2C9 inhibition)
2. **Warfarin + Rifampin** → ↓INR (CYP3A4/2C9 induction)
3. **Statins + Azole antifungals** → Rhabdomyolysis (CYP3A4 inhibition)
4. **Digoxin + Verapamil** → Digoxin toxicity (P-gp inhibition)
5. **Clopidogrel + Omeprazole** → ↓antiplatelet effect (CYP2C19 inhibition)
6. **MAOIs + SSRIs** → Serotonin syndrome
7. **Sildenafil + Nitrates** → Severe hypotension (contraindicated)
8. **Theophylline + Ciprofloxacin** → Theophylline toxicity (CYP1A2 inhibition)
9. **Methotrexate + NSAIDs** → MTX toxicity (↓renal excretion)
10. **ACE-I + K+-sparing diuretics** → Hyperkalemia
11. **β-blockers + Verapamil/Diltiazem** → Bradycardia, heart block
12. **Linezolid (MAOI) + SSRIs** → Serotonin syndrome
13. **Azole antifungals + Ketoconazole-dependent drugs** → ↓absorption (pH)
14. **Grapefruit juice + Simvastatin** → ↑statin levels (intestinal CYP3A4)
15. **Fluoroquinolones + Antacids/dairy** → ↓antibiotic absorption (chelation)
16. **Alcohol + Metronidazole** → Disulfiram-like reaction
17. **Valproic acid + Lamotrigine** → ↑lamotrigine, rash risk (UGT inhibition)
18. **St. John's wort + OCPs** → Contraceptive failure (CYP3A4 induction)
19. **NSAIDs + ACE-I + Diuretic** → Acute kidney injury (triple whammy)
20. **Amiodarone + Warfarin** → ↑INR (CYP2C9 inhibition)

---

## Clinical Pearls

1. **Most interactions are predictable**: Know CYP450 system
2. **Narrow TI drugs**: Highest interaction risk (warfarin, digoxin, phenytoin)
3. **Elderly at highest risk**: Polypharmacy, altered PK/PD
4. **Inducers take weeks**: Plan ahead when starting/stopping
5. **Inhibitors are immediate**: Monitor closely when starting
6. **Rifampin is nuclear**: Induces almost everything
7. **Azoles are powerful inhibitors**: Especially ketoconazole
8. **P-gp interactions often overlooked**: Important for digoxin, DOACs
9. **Protein binding displacement**: Usually transient, less important than once thought
10. **QT prolongation**: Check ECG with multiple QT drugs
11. **Serotonin syndrome**: AVOID MAOIs + SSRIs
12. **Triple whammy**: ACE-I + NSAID + diuretic → AKI
13. **Sildenafil + nitrates**: Absolutely contraindicated
14. **Grapefruit juice effects last >24h**: Irreversible CYP3A4 inhibition
15. **TMP-SMX**: Multiple interactions (CYP2C9, warfarin, creatinine secretion, K+)

---

## Key Takeaways

1. **Drug interactions are common** and often preventable
2. **Pharmacokinetic interactions** involve ADME processes
3. **Pharmacodynamic interactions** involve drug effects
4. **CYP450 system** responsible for most metabolic interactions
5. **Know major CYP isoforms**: 3A4, 2D6, 2C9, 2C19, 1A2
6. **Enzyme inducers** decrease drug levels (CRAP GPS)
7. **Enzyme inhibitors** increase drug levels
8. **P-glycoprotein** affects absorption and distribution
9. **Narrow TI drugs** most susceptible to interactions
10. **Elderly and polypharmacy** highest risk
11. **Always check for interactions** before prescribing
12. **Multiple management strategies** available
13. **Patient education** essential
14. **Documentation** important for safety and medicolegal reasons

---

## References

1. Katzung's Basic & Clinical Pharmacology, 15th Edition
2. Drug Interactions: Analysis and Management, Hansten & Horn
3. Lexi-Interact Online Drug Interactions Database
4. Micromedex Drug Interactions
5. FDA Drug Safety Communications
6. ISMP High-Alert Medications
7. Clinical Pharmacology and Therapeutics Journal
8. Stockley's Drug Interactions, 12th Edition
